In medicinal chemistry, dihydrofolate reductase (DHFR) has gained attention as a promising therapeutic target, especially in the treatment of conditions such as cancer, bacterial infections, malaria and tuberculosis [2,3,4,5,6]. This evidence concerns the gene DHFR and bacterial infectious disease.